Vaccine, 2013-02, Vol.31 (9), p.1340-1348
2013
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial
- Ist Teil von
- Vaccine, 2013-02, Vol.31 (9), p.1340-1348
- Ort / Verlag
- Kidlington: Elsevier Ltd
- Erscheinungsjahr
- 2013
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Highlights ► The recombinant BCG vaccine VPM1002 was tested in PPD+ and PPD− individuals. ► VPM1002 successfully completed a phase I clinical trial. ► VPM1002 was as safe as BCG. ► VPM1002 and BCG induced both shared and differential immune responses.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0264-410XeISSN: 1873-2518DOI: 10.1016/j.vaccine.2012.12.053Titel-ID: cdi_proquest_miscellaneous_1348489889
- Format
- –
- Schlagworte
- Adolescent, Adult, Allergy and Immunology, antibodies, Antibodies, Bacterial - blood, Antigens, Applied microbiology, B-lymphocytes, bacterial antigens, BCG, BCG vaccine, BCG Vaccine - administration & dosage, BCG Vaccine - adverse effects, BCG Vaccine - genetics, BCG Vaccine - immunology, Biological activity, Biological and medical sciences, blood serum, cell-mediated immunity, Clinical trial, Clinical trials, Cytokines, Enzymes, Flow Cytometry, Fundamental and applied biological sciences. Psychology, Genetic engineering, Healthy Volunteers, Humans, Immune response, Immunogenicity, Injections, Intradermal, interferon-gamma, Interferon-gamma - secretion, Leukocytes, Mononuclear - immunology, Male, Microbiology, Middle Aged, Mycobacterium bovis, Mycobacterium bovis BCG, randomized clinical trials, Safety, Skin, T-lymphocytes, Tuberculosis, Vaccination, Vaccines, Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects), Vaccines, Synthetic - administration & dosage, Vaccines, Synthetic - adverse effects, Vaccines, Synthetic - genetics, Vaccines, Synthetic - immunology, volunteers, Young Adult